Avian Cell, Per Se Patents (Class 435/349)
-
Publication number: 20120156771Abstract: A transgenic chicken is disclosed having disrupted endogenous immunoglobulin production. In one embodiment, a targeting construct is stably integrated into the genome of the chicken by homologous recombination in embryonic stem cells, and injection of the engineered embryonic stem cells into recipient embryos, thereby knocking out the endogenous immunoglobulin gene locus in resulting animals. The targeted disruption of the locus in embryonic stem cells is particularly useful in combination with the insertion of genetic elements encoding exogenous immunoglobulin molecules. After these chickens are cross-bred, a line of chickens is produced that has a reduction of endogenous immunoglobulin molecule production.Type: ApplicationFiled: October 25, 2011Publication date: June 21, 2012Inventors: Robert J. Etches, Robert M. Kay, Lei Zhu
-
Publication number: 20120148559Abstract: The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest. The invention's compositions and methods are useful in, for example, therapeutic applications by minimizing adverse immune responses by the host mammalian subjects to the protein of interest.Type: ApplicationFiled: November 30, 2011Publication date: June 14, 2012Applicant: Board of Regents The University of Texas SystemInventors: George Georgiou, Jason Cantor, Tae Hyeon Yoo
-
Publication number: 20120149102Abstract: The invention provides a polypeptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention provides DNA encoding the polypeptide, as well as vectors and cells comprising the DNA and methods comprising the administration of the polypeptide.Type: ApplicationFiled: February 17, 2012Publication date: June 14, 2012Applicants: Human ServiceInventors: Jeffrey Schlom, Elene Barzaga, Sam Zaremba
-
Patent number: 8187884Abstract: The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible. The production of antibodies that bind specifically to antigens from cell populations in which the antibody molecules have been diversified by the enhancement of somatic homologous recombination is made possible by using an appropriate selection method (for example, beads coated with antigen and the like).Type: GrantFiled: June 10, 2010Date of Patent: May 29, 2012Assignees: Riken, Chiome Bioscience, Inc.Inventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Publication number: 20120128723Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: ApplicationFiled: November 16, 2011Publication date: May 24, 2012Applicant: VIVENTIA BIOTECHNOLOGIES INC.Inventors: Francina C. CHAHAL, Joycelyn ENTWISTLE, Jeannick CIZEAU, Nicholas Ronald GLOVER, Glen Christopher MACDONALD
-
Publication number: 20120122150Abstract: The present invention provides methods for stabilizing a biological sample for analysis. The invention more particularly provides methods combining heat treatment and chemical fixation of biological samples in order to maintain protein primary structure and post-translational modifications, such as protein phosphorylations.Type: ApplicationFiled: June 8, 2010Publication date: May 17, 2012Applicant: DENATOR AKTIEBOLAGInventors: Mats Borén, Karl Skdöld, Marcus Svensson
-
Publication number: 20120122155Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: May 11, 2010Publication date: May 17, 2012Applicant: TRANSGENE S.A.Inventors: Jean-Marc BALLOUL, Marina KAPFER, Thierry MENGUY
-
Publication number: 20120094294Abstract: Eukaryotic cells having upregulated BMS1 genes and a nucleotide sequence encoding a recombinant protein or fragment for the production of such proteins or fragments are provided. This is based on the finding that elevated BMS1 levels, improve yields of recombinant proteins. Methods of producing recombinant proteins using such cells are also provided.Type: ApplicationFiled: July 17, 2009Publication date: April 19, 2012Inventors: Nicklas Bonander, Richard Darby, Roslyn Bill, Ljuban Grgic
-
Publication number: 20120093872Abstract: The present invention relates to a method for polypeptide transfer into cells. The present invention further relates to the detection of polypeptide-specific immune cells and the priming, expansion and reactivation of polypeptide-specific T cells. Moreover the present invention relates to polypeptides of the methods of the present invention in combination with urea and their use for research, diagnosis or treatment and prevention of diseases in animals and humans.Type: ApplicationFiled: April 9, 2010Publication date: April 19, 2012Applicant: LOPHIUS BIOSCIENCES GMBHInventors: Sascha Barabas, Katrin Edmaier, Ludwig Deml
-
Publication number: 20120084871Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.Type: ApplicationFiled: February 14, 2011Publication date: April 5, 2012Applicant: Schering CorporationInventors: Scott Altmann, Xiaorui Yao, Kim Anne O'Neill, Brian E. Hawes
-
Publication number: 20120083033Abstract: A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.Type: ApplicationFiled: July 8, 2011Publication date: April 5, 2012Inventors: ALEX J. HARVEY, JEFFREY C. RAPP
-
Publication number: 20120077268Abstract: The present invention relates to a process for culturing animal cells, e.g., human, diploid anchorage-dependent cells, in the absence of exogenous components of primary animal origin. In particular, the invention provides cell culture media substantially free of exogenous components of primary and secondary animal origin which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal cells using a protease of non-animal origin for passaging cells.Type: ApplicationFiled: October 10, 2011Publication date: March 29, 2012Applicant: GlaxoSmithKline Biologicals, s.a.Inventors: Brigitte Ghislaine Louise Aerts, Yves Jules Maurice Ghislain, Marie-Monique Jane Gonze, Isabelle Solange Lucie Knott, Carine Maggetto
-
Publication number: 20120079616Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.Type: ApplicationFiled: October 12, 2011Publication date: March 29, 2012Applicant: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
-
Publication number: 20120070893Abstract: The present invention relates to a method for producing avian cell lines, comprising gradual or complete withdrawal of growth factors, serum and/or feeder layer so that the established lines are adherent or nonadherent cells capable of proliferating indefinitely in a basic culture medium. The invention also relates to the cells derived from such lines which are particularly useful for the production of substances of interest.Type: ApplicationFiled: March 3, 2010Publication date: March 22, 2012Applicant: VIVALISInventors: Bertrand PAIN, Fabienne Guehenneux
-
Publication number: 20120064518Abstract: Methods, tip assemblies and kits are provided for introducing material into cells. The tip assemblies include an attachment portion, a channel portion, and a constriction that function to reduce fluid pressure as a fluid passes through the constriction portion from the channel portion, whereby the tip assemblies form pores in the membranes of cells and introduce material into the cells. The material includes for example one selected from the group of: an inorganic compound, a drug, a genetic material, a protein, a carbohydrate, a synthetic polymer, and a pharmaceutical composition.Type: ApplicationFiled: September 13, 2011Publication date: March 15, 2012Applicant: TUFTS UNIVERSITYInventor: Thomas J. Diefenbach
-
Publication number: 20120064081Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.Type: ApplicationFiled: January 15, 2010Publication date: March 15, 2012Applicant: INNATE PHARMAInventors: Nicolas Anfossi, Laurent Gauthier, Yannis Morel, Alessandro Moretta, Silvia Parolini, Benjamin Rossi
-
Publication number: 20120065251Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.Type: ApplicationFiled: January 19, 2010Publication date: March 15, 2012Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David
-
Publication number: 20120064622Abstract: The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest.Type: ApplicationFiled: October 31, 2011Publication date: March 15, 2012Applicant: GINKGO BIOWORKSInventors: CURT R. FISCHER, AUSTIN J. CHE, RESHMA P. SHETTY, JASON R. KELLY
-
Publication number: 20120064112Abstract: The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector.Type: ApplicationFiled: July 21, 2011Publication date: March 15, 2012Applicant: THE UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: SIBA K. SAMAL, ZHUHUI HUANG
-
Publication number: 20120053321Abstract: Novel methods are disclosed for forming a heterodimeric receptor complex with IL-28R and CRF2-4. The methods may be used for detecting and treating viral infections in in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: October 4, 2011Publication date: March 1, 2012Inventors: Wenfeng Xu, Stacy Schlutsmeyer, Cameron S. Brandt, Wayne R. Kindsvogel, Katherine E. Henderson, Theodore E. Whitmore, Kevin M. Klucher
-
Publication number: 20120052570Abstract: The present invention relates to a method for tightly temporally controlling the biological activity of a protein of interest in a vertebrate, upon induction of the activity of a fusion protein comprising said protein of interest and an ERM polypeptide containing a mutated ligand binding domain of the human oestrogen receptor ?, with a synthetic ligand that does not interfere with oestrogen signalling. In particular, the present invention concerns a method for generating tightly temporally-controlled targeted somatic mutations in a vertebrate, preferably a mouse, by inducing the activity of a fusion protein comprising a site-specific recombinase protein and an ERM polypeptide, with a synthetic ligand devoid of oestrogenic and anti-oestrogenic activities.Type: ApplicationFiled: January 22, 2010Publication date: March 1, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Daniel Metzger, Pierre Chambon, Huimin Zhao, John Katzenellenbogen
-
Publication number: 20120053232Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: March 1, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120040456Abstract: The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.Type: ApplicationFiled: June 2, 2011Publication date: February 16, 2012Applicant: Baylor College of MedicineInventors: Rando Allikmets, Kent L. Anderson, Michael Dean, Mark Leppert, Richard A. Lewis, Yixin Li, James R. Lupski, Jeremy Nathans, Amir Rattner, Noah F. Shroyer, Nanda Singh, Philip Smallwood, Hui Sun
-
Publication number: 20120034160Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: August 2, 2011Publication date: February 9, 2012Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
-
Publication number: 20120028300Abstract: The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.Type: ApplicationFiled: June 30, 2011Publication date: February 2, 2012Applicant: Intrexon CorporationInventors: Jianzhong ZHANG, Dean Ervin Cress, Subba Reddy Palli, Tarlochan Singh Dhadialla
-
Publication number: 20120028336Abstract: The present invention is directed to a modified poxvirus vector that allows for the generation of recombinant poxviruses by a single recombination event. A modified poxvirus vector comprising at least one reporter gene located between two flanking sequences for homologous recombination is disclosed. Furthermore, a host cell comprising said vector and a method for the generation of recombinant poxviruses using said vector are provided.Type: ApplicationFiled: December 16, 2009Publication date: February 2, 2012Applicant: EMERGENT PRODUCT DEVELOPMENT GERMANY GMBHInventors: Sonja Leyrer, Kaja Mayer
-
Publication number: 20120020940Abstract: The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity.Type: ApplicationFiled: September 24, 2009Publication date: January 26, 2012Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)Inventors: Jörg Durner, Christian Lindermayr, Ruth Brack-Werner
-
Publication number: 20120020934Abstract: The subject invention concern materials and methods for cryopreservation of HCG-cell constructs. In one embodiment, porous HCG scaffolds are provided in a perfusion bioreactor having perfusion chambers that can contain the HCG scaffolds, cells are then seeded in the HCG scaffolds in the perfusion bioreactor, cell culture media is perfused through and the bioreactor operated so as to allow for cell seeding and growth in the HCG scaffold. After a suitable period of time, the cell culture media is removed and the HCG containing cells (HCG-cell constructs) can be washed with a suitable buffer, such as phosphate-buffered saline (PBS). The HCG-cell constructs are then perfused in the bioreactor with a suitable cryopreservation fluid. The cryopreservant can comprise one or more of the following: DMSO, trehalose, glycerol, ethylene glycol, and serum for cell culture (e.g., fetal bovine serum (FBS)).Type: ApplicationFiled: July 15, 2011Publication date: January 26, 2012Applicant: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventor: TENG MA
-
Publication number: 20120021491Abstract: The present invention discloses novel methods for the generation, expression and screening of diverse collections of binding proteins such as antibodies or fragments thereof in vertebrate host cells in vitro, for the identification and isolation of ligand- or antigen-specific binding proteins. The methods disclosed herein allow the expression of diverse collections of binding proteins from at least one vector construct, which optionally can give rise to collections of diverse binding proteins upon transfer and expression into vertebrate host cells in situ.Type: ApplicationFiled: September 29, 2011Publication date: January 26, 2012Applicant: 4-ANTIBODY AGInventors: Ulf GRAWUNDER, Jorn STITZ
-
Publication number: 20120017290Abstract: Disclosed herein are methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a zinc-finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: ApplicationFiled: April 25, 2011Publication date: January 19, 2012Inventors: Xiaoxia Cui, Gregory Davis, Philip D. Gregory, Michael C. Holmes, Edward J. Weinstein
-
Publication number: 20120016008Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human ribosomal protein L26 (RIBO26) and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: January 19, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120015840Abstract: The present invention relates to a method for generating an RNA library or a (poly)peptide library comprising the steps of: (a) providing one or more nucleic acid molecules each comprising i) two or more coding elements (A) each giving rise to an RNA molecule upon transcription and/or a (poly)peptide upon transcription and translation; and ii) linking elements (B) arranged according to the general formula of B(AB)2+n, wherein said linking elements comprise one or more sequence motifs not found in said two or more coding elements allowing specific disruption of the linking elements (B); (b) cloning the nucleic acid molecule of step (a) into a vector; (c) transforming a host cell with the vector obtained in step (b) and propagating said transformed cell; (d) preparing vector DNA from the transformed and propagated cells of step (c); (e) (i) disrupting the vector DNA obtained in step (d) with one or more agents recognizing said one or more sequence motifs of the linking elements or (ii) performing an amplificatiType: ApplicationFiled: January 22, 2010Publication date: January 19, 2012Inventor: Michael Lebens
-
Publication number: 20120010268Abstract: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 encoding HASH2 and methods of use.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010269Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human SMS3 (SMS3) and methods of use.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010270Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120003740Abstract: This document discloses electroporation vessels, electrocompetent cells that have been aliquoted and frozen in electroporation vessels, and a number of other apparatuses, kits, and methods for electroporation. Some embodiments of electroporation vessels described herein may include a pair of opposing walls that are downwardly angled toward one another in a gap between two electrode surfaces. Further embodiments of devices and methods described herein may eliminate the need for an end user to transfer competent cells from a capped tube to electroporation cuvette, thereby saving time and producing less waste.Type: ApplicationFiled: December 28, 2010Publication date: January 5, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Laura Vozza-Brown, Harry Yim, John Cameron, Matthew O'Banion, Adam Scott Henry, Lisa Marie Olivier
-
Publication number: 20120004178Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: May 17, 2011Publication date: January 5, 2012Inventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
-
Publication number: 20110306126Abstract: Disclosed is a method for producing an antibody directed against a protein, particularly a transmembrane protein, expressed on the surfaces of cells. Specifically disclosed is a means for obtaining a desired antibody by mixing cells capable of expressing an antigen protein on the surfaces thereof (i.e., antigen molecule-expressing cells) with an antibody library composed of antibody-expressing cells, viruses or the like, and subsequently concentrating/isolating only components (e.g., antibody-expressing cells, viruses) capable of binding to the antigen molecule-expressing cells from the components (e.g., antibody-expressing cells, viruses) of the antibody library.Type: ApplicationFiled: December 7, 2009Publication date: December 15, 2011Applicant: CHIOME BIOSCIENCE INC.Inventors: Shu-ichi Hashimoto, Donghui LI, Shoko Ishida, Hidetaka Seo, Chika Koyama, Yukiko Banzai, Naoto Harigai, Isao Kohno
-
Publication number: 20110294209Abstract: The present invention relates to a method for producing avian cell lines, comprising gradual or complete withdrawal of growth factors, serum and/or feeder layer so that the established lines are adherent or nonadherent cells capable of proliferating indefinitely in a basic culture medium. The invention also relates to the cells derived from such lines which are particularly useful for the production of substances of interest.Type: ApplicationFiled: August 9, 2011Publication date: December 1, 2011Applicant: VIVALISInventors: Bertrand Pain, Fabienne Guehenneux
-
Publication number: 20110293656Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.Type: ApplicationFiled: May 18, 2011Publication date: December 1, 2011Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
-
Publication number: 20110281282Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: ApplicationFiled: November 11, 2010Publication date: November 17, 2011Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20110269119Abstract: Methods and apparatus are disclosed herein for encoding human readable text conveying a non-genetic message into nucleic acid sequences with a substantially reduced probability of biological impact and decoding such text from nucleic acid sequences. In one embodiment, each symbol of a symbol set of human readable symbols uniquely maps to a respective codon identifier. Mapping may ensure that each symbol will not map to a codon identifier that generates an amino acid residue which has a single-letter abbreviation that is the equivalent to the respective symbol. Synthetic nucleic acid sequences comprising such human readable text, and recombinant or synthetic cells comprising such sequences are provided, as well as methods of identifying cells, organisms, or samples containing such sequences.Type: ApplicationFiled: October 29, 2010Publication date: November 3, 2011Applicant: Synthetic Genomics, Inc.Inventors: Clyde A. Hutchison, Michael G. Montague, Hamilton O. Smith
-
Publication number: 20110262902Abstract: The invention relates to identification of a cis-acting diversification activator (DIVAC) that is necessary and sufficient for the activation of diversification in transcription units linked thereto. The invention provides a method for diversification of a target nucleic acid comprising introducing a genetic construct comprising the diversification activator into a recipient cell, wherein the diversification activator is linked to the target nucleic acid.Type: ApplicationFiled: April 9, 2009Publication date: October 27, 2011Applicant: Heimholz Zentrum Munchen Deutsches Forschungszen- trum fur Gesundheit und Umwelt (GmbHInventors: Randolph B Caldwell, Jean-Marie Buerstedde, Ulrike Schötz
-
Publication number: 20110265198Abstract: Disclosed herein are methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a DNA binding domain and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: ApplicationFiled: April 25, 2011Publication date: October 27, 2011Inventors: Philip D. Gregory, Michael C. Holmes
-
Publication number: 20110256622Abstract: The present invention provides methods for the culture of animal pluripotent stem cells and their differentiated progeny cells, tissues, and organs, and nonhuman animal embryos and fetuses.Type: ApplicationFiled: June 29, 2011Publication date: October 20, 2011Inventors: Michael D. West, Karen B. Chapman, Irina V. Klimanskaya
-
Publication number: 20110247091Abstract: The present disclosure provides a transgenic cell or chicken having increased resistance to RNA viral infection, wherein the chicken cell expresses a foreign RIG-I gene. Also provided are methods for reducing RNA virus replication in a chicken cell and methods for producing the transgenic cell or chicken with increased RNA viral resistance.Type: ApplicationFiled: March 25, 2011Publication date: October 6, 2011Inventors: Katharine Edens Magor, Megan Rani Winnifred Barber, Jerry Ronald Aldridge, JR., Robert G. Webster
-
Publication number: 20110229969Abstract: The present invention provides an avian cell that is derived from an avian host cell and stably carries at least one DNA sequence in the cell nucleus encoding an alphavirus polypeptide, a method for preparing such an avian cell, and its use in preparing an alphavirus replican particle.Type: ApplicationFiled: June 25, 2009Publication date: September 22, 2011Inventors: Volker Sandig, Ingo Jordan
-
Publication number: 20110217749Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: ApplicationFiled: May 12, 2011Publication date: September 8, 2011Applicant: BAVARIAN NORDIC A/SInventors: INGMAR RATHE, EVA FELDER, KARL HELLER
-
Publication number: 20110212094Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: October 28, 2010Publication date: September 1, 2011Applicant: ABBOTT LABORATORIESInventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
-
Publication number: 20110212488Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxyiridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: May 11, 2010Publication date: September 1, 2011Applicant: TRANSGENE S.A.Inventors: Jean-Marc BALLOUL, Marina KAPFER, Thierry MENGUY